ANDRE NEDER RAMIRES ABDO
Índice h a partir de 2011
8
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
3 resultados
Resultados de Busca
Agora exibindo 1 - 3 de 3
article 20 Citação(ões) na Scopus Efficacy and Safety Results From ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase Previously Treated With >= 2 Tyrosine Kinase Inhibitors(2021) HOCHHAUS, Andreas; BOQUIMPANI, Carla; REA, Delphine; MINAMI, Yosuke; LOMAIA, Elza; VOLOSHIN, Sergey; TURKINA, Anna G.; KIM, Dong-Wook; APPERLEY, Jane; CORTES, Jorge E.; ABDO, Andre; FOGLIATTO, Laura Maria; KIM, Dennis Dong Hwan; COUTRE, Philipp D. le; SAUSSELE, Susanne; ANNUNZIATA, Mario; HUGHES, Timothy P.; CHAUDHRI, Naeem A.; CHEE, Lynette C. Y.; GUTIERREZ, Valentin Garcia; SASAKI, Koji; AIMONE, Paola; ALLEPUZ, Alex; QUENET, Sarah; BEDOUCHA, Veronique; MAURO, Michael J.- Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First -in -Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after >= 2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks(2021) MAURO, Michael J.; MINAMI, Yosuke; REA, Delphine; HOCHHAUS, Andreas; LOMAIA, Elza; VOLOSHIN, Sergey; TURKINA, Anna G.; KIM, Dong-Wook; APPERLEY, Jane F.; CORTES, Jorge E.; ABDO, Andre N. R.; FOGLIATTO, Laura; KIM, Dennis Dong Hwan; COUTRE, Philipp D. le; SAUSSELE, Susanne; ANNUNZIATA, Mario; HUGHES, Timothy P.; CHAUDHRI, Naeem A.; CHEE, Lynette C. Y.; GUTIERREZ, Valentin Garcia; SASAKI, Koji; KAPOOR, Shruti; ALLEPUZ, Alex; QUENET, Sarah; BEDOUCHA, Veronique; BOQUIMPANI, Carla
- A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs(2021) REA, Delphine; MAURO, Michael J.; BOQUIMPANI, Carla; MINAMI, Yosuke; LOMAIA, Elza; VOLOSHIN, Sergey; TURKINA, Anna; KIM, Dong-Wook; APPERLEY, Jane F.; ABDO, Andre; FOGLIATTO, Laura Maria; KIM, Dennis Dong Hwan; COUTRE, Philipp le; SAUSSELE, Susanne; ANNUNZIATA, Mario; HUGHES, Timothy P.; CHAUDHRI, Naeem; SASAKI, Koji; CHEE, Lynette; GARCIA-GUTIERREZ, Valentin; CORTES, Jorge E.; AIMONE, Paola; ALLEPUZ, Alex; QUENET, Sara; BEDOUCHA, Veronique; HOCHHAUS, AndreasPatients with chronic myeloid leukemia in chronic phase (CML-CP) resistant/intolerant to >= 2 tyrosine kinase inhibitors (TKIs) are at high risk of experiencing poor outcomes because of disease biology and inadequate efficacy and/or safety of current therapies. Asciminib, a first-in-class BCR-ABL1 inhibitor Specifically Targeting the ABL Myristoyl Pocket (STAMP), has the potential to overcome resistance/intolerance to approved TKIs. In this phase 3, open-label study, patients with CML-CP previously treated with >= 2 TKIs were randomized (2:1) to receive asciminib 40 mg twice daily vs bosutinib 500 mg once daily. Randomization was stratified by major cytogenetic response (MCyR) status at baseline. The primary objective was to compare the major molecular response (MMR) rate at week 24 for asciminib vs bosutinib. A total of 233 patients were randomized to asciminib (n = 157) or bosutinib (n = 76). Median follow-up was 14.9 months. The MMR rate at week 24 was 25.5% with asciminib and 13.2% with bosutinib. The difference in MMR rate between treatment arms, after adjusting for MCyR at baseline, was 12.2% (95% confidence interval, 2.19-22.30; 2-sided P = .029). Fewer grade >= 3 adverse events (50.6% vs 60.5%) and adverse events leading to treatment discontinuation (5.8% vs 21.1%) occurred with asciminib than with bosutinib. The study showed a superior efficacy of asciminib compared with that of bosutinib, together with a favorable safety profile. These results support the use of asciminib as a new therapy in patients with CML-CP who are resistant/intolerant to >= 2 prior TKIs.